Equivalent API for Stimate Nasal Spray Manufacturing

Resolving Peptide Solubility Anomalies in Aqueous Nasal Buffers (pH 5.5–6.0) for Stimate-Equivalent Formulations

When formulating a nasal spray equivalent to Stimate, one of the first hurdles R&D managers encounter is the solubility behavior of desmopressin acetate in the target buffer system. Stimate nasal spray is formulated at a concentration of 0.1 mg/mL desmopressin acetate (equivalent to 0.089 mg/mL desmopressin free base) in an aqueous solution with chlorobutanol as preservative, adjusted to pH 5.5–6.0. While desmopressin acetate is freely soluble in water, subtle shifts in pH, ionic strength, or the presence of trace metal ions can induce aggregation or precipitation, particularly during long-term storage. From our field experience, a non-standard parameter that often goes unnoticed is the impact of residual trifluoroacetic acid (TFA) from peptide synthesis. Even at levels below 0.1%, TFA can lower the microenvironmental pH upon reconstitution, leading to gradual formation of insoluble fibrils. We recommend requesting a batch-specific COA that includes TFA content by ion chromatography. Additionally, pre-dissolution in a small volume of dilute acetic acid (0.1% v/v) before buffer addition can mitigate localized pH excursions. For a seamless drop-in replacement, our desmopressin acetate is manufactured under strict GMP standards with controlled counterion stoichiometry, ensuring consistent solubility profiles that mirror the reference listed drug. For those exploring tablet-based alternatives, our drop-in API replacement for DDAVP tablet formulations provides parallel insights into solid-dosage performance.

Microcrystalline Particle Size Engineering: Achieving D90 <10 µm to Prevent Actuator Nozzle Clogging

Although desmopressin acetate is delivered as a solution in Stimate, the physical stability of the spray is heavily influenced by the particle size distribution of the raw API. During manufacturing, incomplete dissolution or subsequent recrystallization can generate microcrystals that clog the actuator nozzle, leading to inconsistent dosing. To prevent this, we engineer our desmopressin acetate to exhibit a D90 particle size below 10 µm, with a narrow span (D10–D90) to minimize fines and oversize particles. This is achieved through controlled lyophilization and jet-milling under inert conditions. A critical edge case occurs when the API is stored in high-humidity environments: amorphous content can absorb moisture and promote crystal growth. We recommend storing the API in double-lined aluminum foil bags with desiccant, and performing a dissolution stress test (e.g., 24-hour stirring in buffer at 25°C) to confirm absence of visible particulates before scale-up. Our technical team can provide particle size data by laser diffraction (Malvern Mastersizer) and scanning electron microscopy images upon request. For a broader perspective on peptide API sourcing, our substituto direto de API para formulações de comprimidos de DDAVP discusses similar particle engineering challenges in tablet manufacturing.

Crystal Habit Control and Its Impact on Spray Plume Geometry in High-Speed Filling Operations

Beyond particle size, the crystal habit of desmopressin acetate can subtly influence the spray plume geometry, which is critical for bioequivalence. Stimate’s actuator is designed to deliver a fine mist with a specific droplet size distribution (typically Dv50 around 30–50 µm). If the API contains needle-shaped crystals, they may align under shear during filling, leading to transient viscosity increases and altered spray patterns. Our crystallization process is optimized to produce equant or plate-like crystals, which exhibit more Newtonian flow behavior in solution. A non-standard parameter we monitor is the aspect ratio of crystals via image analysis; an aspect ratio >3:1 can indicate a risk of shear-induced alignment. In one case, a client observed intermittent spray weight variation during high-speed filling (200 bottles/min). Root cause analysis traced the issue to a batch with elongated crystals that partially oriented in the dip tube. Switching to our controlled-habit desmopressin acetate resolved the problem. We also recommend evaluating the spray pattern and plume geometry using a SprayVIEW® or equivalent system during formulation development. As a synthetic vasopressin analogue, desmopressin acetate must meet stringent performance benchmarks to qualify as a true drop-in replacement for Stimate manufacturing.

Drop-in Replacement Strategy: Matching Stimate’s Performance with Desmopressin Acetate from NINGBO INNO PHARMCHEM

For R&D managers seeking a reliable, cost-effective equivalent API for Stimate nasal spray manufacturing, NINGBO INNO PHARMCHEM offers a pharmaceutical-grade desmopressin acetate that serves as a seamless drop-in replacement. Our product is manufactured under ICH Q7 GMP guidelines, with full traceability and batch-to-batch consistency. Key technical parameters include:

• Assay (HPLC): 98.0–102.0% on anhydrous, acetate-free basis
• Specific optical rotation: -72° to -82° (c=1, 1% acetic acid)
• Water content (Karl Fischer): ≤6.0%
• Residual solvents: Complies with USP <467> Class 3 limits
• Peptide purity: ≥99.0% by area normalization; individual impurity ≤0.5%
• Endotoxins: <0.5 EU/mg (for parenteral-grade applications)

We understand that supply chain reliability is paramount. Our logistics network supports flexible packaging options, including 210L drums and IBC totes, with secure, climate-controlled shipping. While we do not claim EU REACH compliance, our packaging is designed to maintain product integrity during transit. For a true performance benchmark, we encourage side-by-side comparative testing against the innovator product. Our high-purity desmopressin acetate API has been validated in multiple nasal spray formulations, demonstrating equivalent bioavailability and stability.

Frequently Asked Questions

Why was Stimate discontinued?

Stimate (desmopressin acetate nasal spray) was discontinued by the manufacturer in 2020 due to business reasons, not safety or efficacy concerns. The decision left many patients and healthcare providers seeking alternative sources of desmopressin. This has increased demand for compounding pharmacies and generic manufacturers to produce equivalent formulations using high-quality desmopressin acetate API.

What is the brand name of Stimate?

Stimate is the brand name for desmopressin acetate nasal spray, originally marketed by CSL Behring. It was specifically indicated for the treatment of bleeding episodes in patients with mild hemophilia A or type I von Willebrand disease. The same active ingredient is also sold under other brand names such as DDAVP, Minirin, and Noctiva for different indications.

What is a substitute for desmopressin?

Desmopressin acetate is the direct substitute for desmopressin in pharmaceutical formulations. As a synthetic peptide hormone, it is available from multiple global manufacturers as a bulk API. For nasal spray manufacturing, a GMP-grade desmopressin acetate with controlled particle size and purity profile can serve as a drop-in replacement for the original Stimate formulation. Other therapeutic alternatives include vasopressin, but desmopressin is preferred due to its higher selectivity for V2 receptors and longer half-life.

What is the concentration of Stimate nasal spray?

Stimate nasal spray contains desmopressin acetate at a concentration of 0.1 mg/mL (equivalent to 0.089 mg/mL desmopressin free base). Each spray delivers 0.1 mL (10 mcg) of solution. The formulation includes chlorobutanol as a preservative and is adjusted to pH 5.5–6.0. When sourcing an equivalent API, it is critical to match this concentration precisely to ensure therapeutic equivalence.

Sourcing and Technical Support

As a leading manufacturer of peptide APIs, NINGBO INNO PHARMCHEM is committed to supporting your formulation development with robust technical data, custom synthesis capabilities, and reliable global logistics. Whether you need a Minirin raw material equivalent or a DDAVP intermediate for further processing, our team can provide comprehensive COA documentation and batch samples for evaluation. We invite you to discuss your specific requirements, from bulk price negotiations to custom particle size specifications. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.